CAPTRUST Financial Advisors
ARQT icon

CAPTRUST Financial Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

CAPTRUST Financial Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$292K Buy
11,129
+839
+8% +$19.5K ﹤0.01% 2614
2026
Q1 		$242K Sell
10,290
-389
-4% -$9.93K ﹤0.01% 2549
2025
Q4 		$310K Buy
+10,679
New +$273K ﹤0.01% 2230
2022
Q3 		– Sell
-95
Closed -$2K – 2187
2022
Q2 		$2K Buy
+95
New +$1.95K ﹤0.01% 4421

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAPTRUST Financial Advisors's ARQT Position: Q2 2026 in Review

CAPTRUST Financial Advisors increased its Arcutis Biotherapeutics (ARQT) stake by 8.2% in Q2 2026, buying an estimated $19.5K and bringing the position to 11,129 shares worth $292K. The position accounts for ﹤0.01% of the portfolio, ranked #2614.

CAPTRUST Financial Advisors first reported a position in ARQT in Q2 2022 and has held it in 4 quarters since. The position peaked at $310K in Q4 2025. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • CAPTRUST Financial Advisors held 11,129 shares of Arcutis Biotherapeutics worth $292K as of Q2 2026.
  • CAPTRUST Financial Advisors bought 839 Arcutis Biotherapeutics shares in Q2 2026, an estimated $19.5K.
  • Arcutis Biotherapeutics made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #2614 holding.
  • CAPTRUST Financial Advisors first reported a position in Arcutis Biotherapeutics in Q2 2022 and has held it in 4 quarters since.
  • CAPTRUST Financial Advisors's Arcutis Biotherapeutics position peaked at $310K in Q4 2025.
  • 273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.